Secondary Logo

Journal Logo

Institutional members access full text with Ovid®


Park, Krystal, BS; Sioufi, Kareem, MD; Shields, Carol L., MD

Retinal Cases and Brief Reports: April 2019 - Volume 13 - Issue 2 - p 108–110
doi: 10.1097/ICB.0000000000000555
Case Report

Purpose: To report a case of clinically invisible retinoblastoma recurrence detected only on spectral-domain optical coherence tomography.

Methods: Case report.

Results: A 3-week-old girl with bilateral familial retinoblastoma underwent six cycles of intravenous chemoreduction. Both eyes showed tumor regression. After 6 cycles of chemoreduction, the tumor in the right eye appeared with clinical regression; however, by spectral-domain optical coherence tomography, there was 40 μm increase in thickness and 290 μm increase in basal diameter. Due to tumor proximity of 1.85 mm to the foveola, the recurrence was treated via intraarterial chemotherapy with two cycles of Melphalan 3 mg. After treatment, spectral-domain optical coherence tomography showed complete regression of the recurrent tumor to a flat scar with intact fovea.

Conclusion: Precise submillimeter imaging with spectral-domain optical coherence tomography for monitoring retinoblastoma is important and can allow detection of early recurrences that might be clinically invisible otherwise, as well as surveillance of the fovea.

Clinically invisible submillimeter retinoblastoma recurrence in an infant was detected on spectral-domain optical coherence tomography and documentation of tumor regression after intraarterial chemotherapy was confirmed.

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.

Reprint requests: Carol L. Shields, MD, Ocular Oncology Service, Wills Eye Hospital, 840 Walnut Street, Suite 1440, Philadelphia, PA 19107; e-mail:

Supported by the Eye Tumor Research Foundation, Philadelphia, PA (C.L.S.). The funders had no role in the design or conduct of the study, in the collection, analysis and interpretation of the data, and in the preparation, review, or approval of the manuscript.

None of the authors has any conflicting interests to disclose.

C. L. Shields had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

© 2019 by Ophthalmic Communications Society, Inc.